News & Events
-
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis
C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the... - February 16, 2023
-
February 15, 2023
Airway Therapeutics Joins C-Path’s International Neonatal Consortium
C-Path today announced that Airway Therapeutics, Inc., (“Airway”) a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, has become a member of its International Neonatal Consortium (INC)
-
February 14, 2023
Regulus Therapeutics Joins PKDOC
C-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a voting member. Regulus Therapeutics is a biotech company working to deliver life changing medicines to patients with orphan kidney diseases. The programs in their pipeline target kidney diseases of high unmet need, including ADPKD. PKDOC brings together diverse stakeholders from... -
February 8, 2023
View Now: Webinar – TRxA 2023 Funding Opportunities
C-Path’s Translational Therapeutics Accelerator is a global drug discovery support program that leverages C-Path’s proficiency in translational and regulatory science to bridge the drug development “valley of death.” TRxA accomplishes this by providing academic researchers with funding and guidance to define optimal strategies to advance cutting-edge new therapeutics from the lab to clinical trials and, ultimately, patient care.
